Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia

/PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug...

Related Keywords

United States ,China ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Jatinj Shah ,Huax Menin ,Patricias Andrews , ,Prnewswire Sumitomo Pharma Oncology Inc ,Sumitomo Pharma Co Ltd ,Drug Administration ,Sumitomo Pharma Oncology Inc ,Pharma Oncology ,Orphan Drug Designation ,Global Head ,Sumitomo Pharma Oncology ,Drug Designation ,Chief Medical Officer ,Private Securities Litigation Reform Act ,Myeloid Leukemia ,Updated July ,Future Med ,Nc ,